Novavax, Inc. (NVAX)
12.56
+2.10
(+20.08%)
USD |
NASDAQ |
Oct 05, 16:00
12.60
+0.04
(+0.32%)
After-Hours: 05:47
Novavax Cash from Operations (Quarterly) : -72.81M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -72.81M |
| March 31, 2026 | -32.42M |
| December 31, 2025 | -39.48M |
| September 30, 2025 | 107.80M |
| June 30, 2025 | -127.46M |
| March 31, 2025 | -185.50M |
| December 31, 2024 | -173.16M |
| September 30, 2024 | -144.81M |
| June 30, 2024 | 314.27M |
| March 31, 2024 | -83.56M |
| December 31, 2023 | -176.78M |
| September 30, 2023 | -39.66M |
| June 30, 2023 | -171.94M |
| March 31, 2023 | -329.18M |
| December 31, 2022 | -117.82M |
| September 30, 2022 | -38.71M |
| June 30, 2022 | -170.90M |
| March 31, 2022 | -88.51M |
| December 31, 2021 | -342.41M |
| September 30, 2021 | -142.14M |
| June 30, 2021 | 144.41M |
| March 31, 2021 | 663.08M |
| December 31, 2020 | -128.57M |
| September 30, 2020 | -6.497M |
| June 30, 2020 | 115.63M |
| Date | Value |
|---|---|
| March 31, 2020 | -23.11M |
| December 31, 2019 | -23.74M |
| September 30, 2019 | -32.26M |
| June 30, 2019 | -30.01M |
| March 31, 2019 | -50.61M |
| December 31, 2018 | -45.27M |
| September 30, 2018 | -33.51M |
| June 30, 2018 | -39.97M |
| March 31, 2018 | -66.08M |
| December 31, 2017 | -35.54M |
| September 30, 2017 | -44.18M |
| June 30, 2017 | -12.40M |
| March 31, 2017 | -44.50M |
| December 31, 2016 | -59.57M |
| September 30, 2016 | -64.97M |
| June 30, 2016 | -63.12M |
| March 31, 2016 | -71.11M |
| December 31, 2015 | -18.25M |
| September 30, 2015 | -28.53M |
| June 30, 2015 | -12.32M |
| March 31, 2015 | -30.79M |
| December 31, 2014 | -19.47M |
| September 30, 2014 | -16.08M |
| June 30, 2014 | -11.07M |
| March 31, 2014 | -21.51M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Merck & Co., Inc. | 5.37B |
| Pfizer Inc. | 835.00M |
| Agenus, Inc. | -31.20M |
| Editas Medicine, Inc. | -29.57M |
| Recursion Pharmaceuticals, Inc. | -105.95M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 34.90M |
| Cash from Financing (Quarterly) | 1.201M |
| Free Cash Flow | -43.02M |
| Free Cash Flow Per Share (Quarterly) | -0.446 |
| Free Cash Flow to Equity (Quarterly) | -75.66M |
| Free Cash Flow to Firm (Quarterly) | -67.52M |
| Free Cash Flow Yield | -2.09% |